Can You Still Have Atrial Fibrillation With a Pacemaker?

Having a pacemaker does not protect you from atrial fibrillation, and AFib episodes can continue, begin for the first time, or even increase after implantation. A pacemaker’s job is to maintain an adequate heart rate when the heart’s electrical system fails to fire or conduct properly. It does not eliminate the chaotic electrical signals in the upper chambers that define AFib. What a pacemaker does remarkably well, though, is detect AFib, often catching episodes that you never feel, which opens a separate set of clinical decisions about stroke prevention and treatment.

Why a Pacemaker Does Not Cure AFib

A pacemaker corrects slow or irregular heartbeats by delivering small electrical impulses to the heart muscle. In most setups, one lead sits in a ventricle and one sits in an atrium, pacing whichever chamber needs help. AFib, by contrast, is a storm of disorganized electrical activity originating in the atrial tissue itself. A pacemaker lead sitting in the atrium can sense this chaos, but it cannot override or silence it. The device is designed to support the heart’s rhythm from below, not to suppress rogue signals from above. So even with a perfectly functioning pacemaker, the atrial tissue remains capable of fibrillating whenever the conditions are right.

Most AFib Episodes in Pacemaker Patients Are Silent

One of the most striking findings in pacemaker research is how few AFib episodes produce symptoms. In a study of 50 pacemaker patients with known paroxysmal AFib, devices recorded a total of 870 episodes. A full 93% of those episodes were completely asymptomatic, occurring roughly 13 times more often than symptomatic ones.¹ This means that for every episode you feel, there could be a dozen or more you never notice.

A separate analysis of 89 pacemaker patients found 1,245 device-stored AFib episodes but also 1,141 patient-reported symptom episodes. The overlap between the two was poor: only about one in five symptom reports actually lined up with a genuine AFib event recorded by the device. The sensitivity of symptoms for detecting AFib was just 19%.² In other words, patients frequently felt something was wrong when it was not AFib, and frequently felt nothing at all when it was. Relying on how you feel turns out to be a terrible way to track this arrhythmia.

Pacemakers as AFib Detectors

While a pacemaker cannot stop AFib, modern dual-chamber devices are continuously monitoring the atrial lead for fast, irregular signals. When the atrial rate exceeds a programmed threshold for a set duration, the device logs it as an atrial high-rate episode. The MOST trial, a large randomized study of over 2,000 patients with sinus node dysfunction, used these pacemaker diagnostics to track atrial high-rate episodes and link them to clinical outcomes like stroke and death.³

This detection ability has revealed just how common subclinical AFib is. Research following patients after dual-chamber pacemaker implantation found that close to 30% of patients with no prior history of AFib developed atrial high-rate episodes lasting five minutes or longer.⁴ Before implantable devices, these brief episodes would have gone entirely unnoticed. Now they raise difficult questions about whether and when to treat.

New-Onset AFib After Pacemaker Implantation

Getting a pacemaker does not just leave you exposed to AFib you already had. A meaningful share of patients develop AFib for the first time after implantation. In a study of 322 elderly patients who received dual-chamber pacemakers, about one in four developed new-onset AFib during follow-up. The strongest predictors were hypertension, older age, an enlarged left atrium, and a high percentage of ventricular pacing.⁵

Another study of 215 patients echoed these findings, reporting that about 26% developed AFib over roughly two and a half years. Among patients whose original pacing indication was sick sinus syndrome, those with a cumulative ventricular pacing percentage of 60% or higher had significantly more new-onset AFib. Larger left atrial size also independently predicted new AFib, particularly in patients with atrioventricular block.⁶ The recurring theme across studies is that how much the ventricle gets paced matters, and that pre-existing atrial enlargement is a red flag.

How Pacing Mode Influences AFib Risk

Not all pacemaker setups carry the same AFib risk. Older-generation single-chamber ventricular (VVI) pacemakers, which pace only the ventricle and ignore the atrium, have a notably poor track record. One study found that nearly 86% of patients paced in VVI mode developed AFib, compared to about 37% of patients in non-VVI modes, a highly significant difference.⁷ Among VVI-paced patients, sick sinus syndrome as the underlying condition made the risk even worse.⁸

Even in dual-chamber systems, the amount of right ventricular pacing appears to be a driver. The Long-MinVPACE study demonstrated that higher right ventricular pacing increased AFib burden in patients who already had paroxysmal AFib. Algorithms designed to minimize unnecessary ventricular pacing reduced both the overall AFib burden and the progression from paroxysmal to persistent AFib over the long term.⁹ The mechanism likely involves the abnormal contraction pattern that right ventricular pacing creates, which over time stretches and remodels the atria in ways that promote fibrillation.

Conduction System Pacing Lowers the Risk

A newer approach called conduction system pacing, where the lead is placed to engage the heart’s natural wiring rather than simply pacing the right ventricular muscle, appears to cut new-onset AFib risk roughly in half. A meta-analysis found new-onset AFib in about 12% of patients with conduction system pacing compared to about 26% with conventional right ventricular pacing.¹⁰ A separate pooled analysis found a similar pattern, with conduction system pacing associated with roughly a 60% lower adjusted risk of developing AFib.¹¹

The reason this works probably comes back to the contraction pattern. Conduction system pacing produces a more natural, coordinated squeeze of the ventricles, which avoids the lopsided mechanical stress that conventional right ventricular pacing places on the atria. This is still a relatively new technique, and not every patient is a candidate, but the AFib reduction is one of the strongest arguments in its favor for patients who need a lot of ventricular pacing.

Atrial Overdrive Algorithms

Some pacemakers include specialized algorithms that try to suppress AFib by pacing the atrium slightly faster than its natural rate, essentially keeping the atrium under constant pacemaker control so that rogue beats have less opportunity to trigger fibrillation. The ADOPT trial tested one such algorithm in patients with paroxysmal AFib and found a 25% reduction in symptomatic AFib burden compared to standard pacing, with atrial pacing percentages rising from about 68% to 93% in the treatment group.¹²

How that overdrive is delivered also matters. A study comparing continuous atrial overdrive pacing with a triggered approach, where overdrive kicks in only after a premature atrial beat is detected, found that the triggered method produced far fewer AFib episodes and a lower overall burden.¹³ These algorithms do not eliminate AFib, but they can meaningfully reduce how much of it occurs. The effect is modest, and not every patient benefits, so expectations should be calibrated accordingly.

Stroke Risk From Pacemaker-Detected AFib

The biggest clinical worry when a pacemaker detects AFib is stroke. Subclinical AFib, the kind only your device knows about, carries roughly 2.5 times the stroke risk compared to patients without it.¹⁴ That sounds alarming, but the absolute risk is lower than it is for clinical AFib detected through symptoms or an ECG in a doctor’s office. And the benefit of blood thinners for device-detected subclinical AFib is less clear-cut than it is for traditional AFib, which makes the treatment decision genuinely difficult.

A study tracking 104 pacemaker patients found that about a third developed AFib episodes over 18 months, with two-thirds of those episodes being completely asymptomatic. Every one of these patients had a stroke risk score that warranted anticoagulation. Yet only about half of the patients who should have been on blood thinners actually received them.¹⁵ This gap between what the evidence calls for and what actually happens in practice is a widespread problem. Some clinicians hesitate to start anticoagulation for brief, asymptomatic episodes, and some patients are reluctant to take blood thinners when they feel perfectly fine. The research on where exactly to draw the line, specifically how long an episode needs to last before it meaningfully raises stroke risk, is still being refined.

Remote Monitoring Catches What Office Visits Miss

Traditionally, pacemaker data was reviewed only at in-office checkups every few months. Remote monitoring systems now transmit device data automatically, allowing clinicians to receive alerts when AFib crosses a programmed threshold. In one study of 160 patients using home monitoring, 26% triggered an AFib alert. Among pacemaker patients specifically, about a third of those with sinus node disease generated alerts. Strikingly, over half of the patients who triggered an AFib alert had no prior history of the arrhythmia at all.¹⁶

Among patients whose AFib was caught by remote monitoring, nearly three-quarters were completely asymptomatic at the time. The clinical response was substantial: about half had their antiarrhythmic medications adjusted, and 45% were started on anticoagulation, including six patients who had never been known to have AFib before their device caught it. Remote monitoring also appears to reduce the total number of days a patient spends in AFib, likely because earlier detection allows earlier intervention.¹⁷ If you have a pacemaker and your clinic offers remote monitoring, it is worth using. The technology turns a device that was implanted for one reason into a continuous arrhythmia surveillance system.

When AFib Undermines Cardiac Resynchronization Therapy

For patients with heart failure who have a cardiac resynchronization therapy (CRT) device, a specialized pacemaker that coordinates the ventricles to pump more efficiently, AFib is a particularly disruptive problem. CRT depends on pacing both ventricles consistently, typically above 98% of the time. When AFib occurs, the fast and irregular signals from the atria can override the pacemaker’s rhythm, causing the device to lose control of ventricular pacing. In an analysis of over 32,000 CRT patients, atrial fibrillation or atrial tachycardia accounted for about 31% of all pacing loss. In the patients with the worst pacing rates, below 90%, AFib was responsible for more than half of the lost pacing.¹⁸

Patients with a history of AFib also tend to get less effective biventricular pacing from their CRT devices overall compared to those without AFib.¹⁹ This creates a frustrating cycle: heart failure predisposes to AFib, and AFib undermines the very device implanted to treat the heart failure. For these patients, aggressive AFib management is not optional; it is essential for the pacemaker to do its job.

The Pace-and-Ablate Strategy

When AFib is persistent and drug therapy has failed to control the ventricular rate, one approach is the “pace-and-ablate” strategy. A surgeon intentionally destroys the atrioventricular node, the electrical bridge between the atria and ventricles, through catheter ablation. This permanently disconnects the atria from the ventricles, making the patient entirely dependent on the pacemaker for their ventricular heartbeat. The atria still fibrillate, but the chaotic signals can no longer reach the ventricles, so the heart rate becomes regular and controllable.²⁰ It is worth emphasizing that this does not cure AFib. It simply removes the symptom of a fast, irregular pulse. Because the atria are still fibrillating, the stroke risk remains, and anticoagulation is still needed. The strategy is typically reserved for patients who have exhausted other options.

Antiarrhythmic Drugs and Pacemaker Interactions

Many pacemaker patients with AFib take antiarrhythmic drugs to reduce the frequency or duration of episodes. These medications work, but they interact with pacemaker function in ways that require monitoring. Certain drugs, particularly flecainide, propafenone, and amiodarone, can raise the pacing threshold, meaning the pacemaker needs more energy to capture the heart. If the pacing output is not adjusted, the device could fail to pace when it needs to.²¹ This effect can be amplified at faster pacing rates, a property called use-dependence that is especially pronounced with class IC drugs like flecainide. After any change in antiarrhythmic medication, pacing thresholds should be rechecked. This is routine for electrophysiologists, but it is the kind of detail that can fall through the cracks if pacemaker follow-up and medication management happen in different offices.

Leadless Pacemakers and AFib Detection Challenges

Leadless pacemakers, small capsule-shaped devices implanted directly inside the heart without wires, represent the newest generation of pacing technology. Most current models sit in the right ventricle and lack a traditional atrial lead. Instead, some newer models attempt to sense atrial contractions mechanically, detecting the physical motion of the atrium rather than its electrical signals. This mechanical sensing works well in many patients but runs into trouble when atrial function is already compromised. A secondary analysis of the MARVEL 2 study found that patients with markers of diastolic dysfunction or atrial disease had weaker mechanical signals, making the sensing algorithm less reliable.²² This is a particular irony: the patients most likely to develop AFib are often the ones whose atrial signals are hardest for a leadless device to detect. As leadless technology matures and dual-chamber leadless systems become available, AFib detection in these devices will be an area to watch closely.